Metformin, pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and the sodium-glucose cotransporter 2 (SGLT2) inhibitor have been studied in patients with MetS. This evidence concerns the gene GLP1R and metabolic syndrome.